sellaslifesciences.com (SLS) Year-over-year earnings per share growth for the last twelve months
The boutique research format of SELLAS Life Sciences (SLS) and the high autonomy of its scientists are accelerating the completion of late-stage R&D for anti-tumor vaccines. The quarterly relative change in EPS visualizes this progress, where 24.00 expresses the current level of the metric. The company's financial stability relies on insurance payments and partnerships with pharma behemoths for the treatment of leukemia.
Financial and market metric breakdowns for SELLAS Life Sciences (SLS)
- share price and expert price forecast:
- market capitalization details:
- book capitalization data:
- debt level and financial liquidity data:
Debt to Equity SELLAS Life Sciences|SLS - Long-Term Debt to Equity|Short-Term Debt to Capital sellaslifesciences.com|SLS - Company Aggregate Debts|Debt to Book Capitalization Ratio SELLAS Life Sciences Group Inc.|SLS - Long-Term Debt Volume|Company Current Liabilities SELLAS Life Sciences|Quick Liquidity sellaslifesciences.com
- earnings and valuation multiples indicators:
SLS - Company Net Income|Projected Future Earnings SELLAS Life Sciences|SLS - Business Payback Period|Forward P/E Multiple sellaslifesciences.com|SLS - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple SELLAS Life Sciences Group Inc.|SLS - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months SELLAS Life Sciences|SLS - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months sellaslifesciences.com|SLS - Expected net earnings per share growth this year|Earnings growth forecast for next year SELLAS Life Sciences
Initial company analysis:SELLAS Life Sciences
Effective asset selection requires analyzing real operational efficiency through the lens of fundamental metrics. Quarterly EPS growth measures the percentage change in net income per share, reflecting the dynamics of return on equity. For SELLAS Life Sciences (SLS), this metric is critical, as the development of leukemia vaccines requires colossal expenditures prior to market entry. It is essential for investors to track how the magnitude of quarterly EPS growth correlates with clinical trial costs. This trend allows for an assessment of the company's financial stability ahead of product commercialization.
Competitors of SELLAS Life Sciences (SLS)
ONC: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Halozyme Therapeutics, Inc. (HALO)|Year-over-year earnings per share growth for the last twelve months RevMed|Ascentage Pharma Corp (AAPG) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth CGON|URGN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Bicara Therapeutics BCAX|Personalis Inc - Year-over-year earnings per share growth for the last twelve months|ERAS - Year-over-year earnings per share growth for the last twelve months|DCTH: Year-over-year earnings per share growth for the last twelve months|YMAB: Quarterly EPS earnings growth|aurabiosciences.com (AURA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Candel Therapeutics Inc.|Accuray Inc (ARAY) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ACTU (Actuate Therapeutics, Inc)|CTOR (Citius Oncology Inc) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months TuHURA Biosciences HURA|protaratx.com - Year-over-year earnings per share growth for the last twelve months|Fate Therapeutics - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Aadi Bioscience Inc WHWK|TCRX: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months CSBR (Champions Oncology, Inc.)|XBIT (XBiotech Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months CEL-SCI Corp CVM|Year-over-year net earnings per share growth for the last 12 months OSTX (OS Therapies)|RADX (Radiopharm Theranostics Ltd) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Artiva Biotherapeutics ARTV|Year-over-year net earnings per share change for the last twelve months Adlai Nortye Ltd (ANL)|Veru Inc. - Quarterly EPS earnings growth|tempesttx.com (TPST) - Year-over-year net earnings per share growth for the last 12 months|XLO: Quarterly EPS earnings growth|RENB - Year-over-year net earnings per share change for the last twelve months|MURA (Mural Oncology PLC) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Kairos Pharma Inc KAPA|Year-over-year earnings per share growth for the last twelve months OnKure Therapeutics Inc (OKUR)|w2.cytomed.sg - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth CRIS (Curis)|APLM - Year-over-year net earnings per share growth for the last 12 months|Tharimmune Corp - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Advanced Biomed Inc|Genprex, Inc. (GNPX) - Year-over-year earnings per share growth for the last twelve months|CLDI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Sunshine Biopharma|Xenetic Bio (XBIO) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Salarius (SLRX)|Year-over-year earnings per share growth for the last twelve months PPBT (Kitov Pharma)|Year-over-year earnings per share growth for the last twelve months American Oncology Network, Inc. AONC|Year-over-year net earnings per share change for the last twelve months beigene.com (BGNE)|Checkpoint Therapeutics, Inc. - Quarterly EPS earnings growth|Elevation Oncology Inc. (ELEV) - Year-over-year net earnings per share growth for the last 12 months|ICAD: Quarterly EPS earnings growth|Ikena Oncology (IKNA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Notable Labs, Ltd.|Year-over-year earnings per share growth for the last 12 months VIRX (Viracta)|Quarterly EPS earnings growth MOR|Year-over-year net earnings per share growth for the last 12 months NAYA Biosciences Inc NAYA|Quarterly EPS earnings growth AAPGV (Ascentage Pharma Group Ltd)
